2003;289:2978 82. 1200. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)- infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613 27. 1201. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiret- roviral drugs on the risk of myocardial infarction in human immuno- deficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228 38. 1202. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201: 318 30. 1203. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebro- vascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702 10. 1204. Khunnawat C, Mukerji S, Havlichek D Jr, et al. Cardiovascular man- ifestations in human immunodeficiency virus-infected patients. Am J Cardiol. 2008;102:635 42. 1205. Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34:937 42. 1206. Lee AB, Godfrey T, Rowley KG, et al. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J. 2006;36:237 43. 1207. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus ery- thematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408 15. 1208. Homcy CJ, Liberthson RR, Fallon JT, et al. 